PBMNasdaqPharmaceutical PreparationsFiscal year ends March 31Also trades as PBMWW
PSYENCE BIOMEDICAL LTD.
Financials through Q2 FY2026, quarter ended Sep 30, 2025Last filing: 20-F on Jun 22, 2026
$4.12−0.10 (-2.37%)
Close on Oct 19, 2026
- Market cap
- $6.10M
- P/E (TTM)
- 0.8
- Dividend yield
- –
Share price
+$0.60 (+17.05%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2025
Valuation
- Market cap
- $6.10M
- P/E ratio
- 0.8
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -61.34%
Fundamentals
- EPS, diluted
- $5.24
- Free cash flow
- -$3.74M
- Diluted shares
- 1M
Four years at a glance
Fiscal years 2022 to 2025, USD
EPS, diluted
$5.24
Free cash flow
-$3.74M
Reported period